Search

Graves orbitopathy, also known as thyroid eye disease, affects around 20% of patients with Graves disease. It is disfiguring and has a significant impact on quality of life. In the past, the standard approach was to wait for the disease to "burn-out" and then perform corrective surgeries. However, high-dose steroids have been shown to reduce symptoms and became the standard of care. In 2017, a failed cancer therapeutic called teprotumumab showed remarkable results in reducing proptosis, leading to an explosion of drug repurposing for this condition. One approach involves using monoclonal antibodies to target the neonatal fragment crystallizable receptor (FcRn). A study using batoclimab, an FcRn inhibitor, showed promising results in reducing proptosis, but the trial was stopped due to adverse effects on LDL and serum albumin levels. These findings provide important insights into the disease process and expand therapeutic options. However, the long-term safety and cost-effectiveness of FcRn inhibitors need to be further investigated. Overall, the paradigm for treating Graves orbitopathy is expected to change in the coming years, with surgery and high-dose steroids playing a smaller role. [Extracted from the article]